Compare RGR & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RGR | VNDA |
|---|---|---|
| Founded | 1949 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.9M | 474.0M |
| IPO Year | 1994 | 2005 |
| Metric | RGR | VNDA |
|---|---|---|
| Price | $38.93 | $8.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $43.00 | $14.90 |
| AVG Volume (30 Days) | 135.6K | ★ 3.4M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 1.16% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $546,057,000.00 | $216,105,000.00 |
| Revenue This Year | $1.05 | $21.50 |
| Revenue Next Year | N/A | $38.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.94 | ★ 8.72 |
| 52 Week Low | $28.33 | $3.81 |
| 52 Week High | $48.21 | $9.91 |
| Indicator | RGR | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 58.11 | 54.51 |
| Support Level | $35.41 | $7.39 |
| Resistance Level | $47.86 | $9.53 |
| Average True Range (ATR) | 1.35 | 0.54 |
| MACD | 0.07 | 0.04 |
| Stochastic Oscillator | 72.24 | 41.58 |
Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.